[Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
Gournay
Jérôme
J
Unité d'Hépatologie, Service de Gastroentérologie et d'Hépatologie, Centre Hospitalier Universitaire, Nantes.
Richou
Carine
C
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D018849:Controlled Clinical Trials as Topic; D003866:Depressive Disorder / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D001523:Mental Disorders / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D011446:Prospective Studies; D011788:Quality of Life; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin